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Summary
Objective: To validate the Knee Injury and Osteoarthritis Outcome Score (KOOS) for the treatment of focal cartilage lesions.
Methods: A total of 40 patients (mean age 35 12 years,) treated for a focal cartilage lesion in the knee were included in this study. Teste
retest data were collected with an intermediate period of 2 days. Patients were asked to complete the Dutch KOOS and complementary
questionnaires [short form-36 (SF-36), Lysholm, EuroQol-5D (EQ-5D)] to evaluate the clinimetric properties of the KOOS in terms of internal
consistency (Cronbach’s alpha), reliability [intra-class-correlation (ICC) and Bland and Altman plots], construct validity (Spearman’s rank cor-
relation), ﬂoor and ceiling effects and responsiveness.
Results: The Cronbach’s alpha of the KOOS subdomains and total score ranged from 0.74 to 0.96. The overall ICC of the KOOS was 0.97
while the subscales ranged from 0.87 to 0.95. The Bland and Altman plots showed a small individual variance between the two assessments
in time. Spearman’s rank correlations between the subscales of the KOOS and representative subscales of the SF-36, Lysholm and EQ-5D
were high to moderate ranging from 0.43 to 0.70. We observed no ﬂoor effect while the largest observed ceiling effect was 10.3%. The re-
sponsiveness was moderate to large with the effect size ranging from 0.70 to 1.32 and the standardized response mean 0.61 to 0.87.
Conclusion: This study illustrates the validity and reliability of the KOOS in measuring the clinical condition of patients after treatment of focal
cartilage lesions. This study provides a basis for the use of the KOOS for future clinical research in cartilage repair.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The growing activity in the ﬁeld of regenerative cartilage
therapy creates a need for validated outcome tools. Several
instruments have been developed to measure the outcome
of such treatment in both research and clinical setting. For
example, the International Cartilage Repair Society (ICRS)
Score and the Oswestry Arthroscopy Score (OAS) have
shown to be useful tools for the macroscopic evaluation of
cartilage repair1. However, patient-reported, self-adminis-
tered questionnaires are preferred as instruments for the
assessment of clinical outcome to prevent from observer
administered bias2. The Western Ontario and McMaster
Universities Index (WOMAC) is a frequently used disease-
speciﬁc questionnaire to measure the treatment effect in pa-
tients with osteoarthritis (OA)3. However, the population
presenting with focal cartilage lesions is generally younger
and more active as compared to patients with OA. There-
fore, the Knee Injury and Osteoarthritis Outcome Score
(KOOS) would ﬁt this population better. The KOOS was de-
veloped as an extension of the WOMAC and designed to
assess short-term and long-term symptoms and function
in younger and/or more active patients with knee injuries,
cartilage damage or different stages of OA4. Validated*Address correspondence and reprint requests to: D. B. F. Saris,
Department of Orthopaedics, University Medical Center Utrecht,
POB 85500, 3508 GA Utrecht, The Netherlands. Tel: 31-88-
756971; Fax: 31-30-2510638; E-mail: d.saris@umcutrecht.nl
Received 12 December 2008; revision accepted 26 April 2009.
1434language versions are available for use in Sweden, Ger-
many, the United States, France, Singapore, Iran and the
Netherlands2,5e8. The KOOS has been validated for several
stages of OA6e8 and for orthopaedic interventions such as
anterior cruciate ligament reconstruction4, meniscectomy2
and total knee replacement9. Recently, short forms of the
WOMAC and KOOS have also been validated for patients
with different stages of OA10,11.
Although already accepted and applied in several clinical
trials to measure the outcome after treatment of focal carti-
lage lesions, the KOOShas not yet been validated for this pa-
tient population12e14. The aim of the present study was to
evaluate the clinimetric properties of the KOOS for patients
with focal cartilage defects, eligible for cartilage repair.MethodsPATIENTSBetween February and April 2008 a total of 60 patients were invited by
phone to participate in this study. All patients had been treated for a symp-
tomatic focal cartilage lesion by either autologous chondrocyte implantation
or microfracturing between February 2002 and July 2006 at the University
Medical Center Utrecht, the Netherlands. The study was approved by and
conducted according to the guidelines of the ethics committee at the Univer-
sity Medical Center of Utrecht.STUDY DESIGN AND QUESTIONNAIRESPatients received two sets of questionnaires (marked as Day 1 and Day
3) by mail, each containing the Dutch KOOS and complementary ques-
tionnaires [short form-36 (SF-36), Lysholm, EuroQol-5D (EQ-5D)] which
Table I
Mean KOOS and reliability of Dutch KOOS subdomains and total
score. The ICC represents the intra-class-correlation whereas the
SDD is the smallest detectable difference
KOOS
subdomain
Mean KOOS (SD) ICC
(95% CI)
SDD
First
assessment
Second
assessment
Symptoms 74 (17) 75 (17) 0.95 (0.90e0.97) 5
Pain 77 (15) 77 (15) 0.92 (0.86e0.96) 6
Function ADL 84 (14) 86 (12) 0.87 (0.77e0.93) 7
Sport/recreation 55 (26) 58 (25) 0.89 (0.81e0.93) 12
QoL 49 (23) 53 (22) 0.95 (0.91e0.97) 7
Total score 74 (15) 76 (14) 0.97 (0.93e0.98) 4
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structed to ﬁll out the ﬁrst set of questionnaires and immediately return
them to the University Medical Center Utrecht using a pre-stamped
envelope. Patients were asked to repeat the assessments with a 2 days
interval18. Each patient was instructed by the investigator to open the sec-
ond set of questionnaires 2 days after the ﬁrst assessment. Scores which
were not completed conform the set time-interval for the testeretest (both
returned on the same day or with a >4-day interval) or those with two or
more missing items in any of the questionnaires were excluded from fur-
ther analysis.
The KOOS is a patient-based, site-speciﬁc, questionnaire that was de-
veloped to be used for short- and long-term follow-up of knee injury and
knee OA. The KOOS comprises ﬁve separately scored subdomains,
based on 42 individual items. The subdomains are symptoms (seven
items), pain (nine items), activities of daily living (ADL) (17 items), function
in sport and recreation (ﬁve items) and knee-related quality-of-life (QoL)
(four items). Each item is scored from 0 (least severe) to 4 (most severe).
For each subdomain as well as the total KOOS the score was normalized
to a 0e100 scale with 100 being the best possible outcome, as previously
described19.
The SF-36 is a widely used patient-based generic QoL questionnaire con-
taining 36 items measuring health in eight domains. These include physical
functioning, role limitations due to physical health problems, role limitations
due to emotional problems, social functioning, vitality, mental health, bodily
pain and general health perceptions. The Dutch version has been validated
by Aaronson et al.15.
The EQ-5D is a questionnaire to measure health-related QoL on the day
of the assessment and contains ﬁve domains, namely, mobility, self-care,
usual activities, pain/discomfort and anxiety/depression and a visual ana-
logue scale (VAS) for overall health. The EQ-VAS is a vertical scale on which
the subject rates their overall health from 0 to 100 (worst to best imaginable,
respectively)16.
The Lysholm knee scoring scale is an eight-item questionnaire designed
for the assessment of symptoms and functional disabilities resulting from
a ligamentous injury. The items include pain, instability, locking, swelling,
limping, walking stairs, squatting and keeping support. Scores are calculated
into one score from 0 to 100 (100 indicating normal knee function). Recently,
the Lysholm knee scoring scale has been validated as an outcome measure
for knee chondral damage17.EVALUATION OF THE CLINIMETRIC PROPERTIESTable II
Internal consistency of the Dutch KOOS subdomains and total score
KOOS subdomains Cronbach’s alpha coefﬁcient
Symptoms 0.74
Pain 0.88
Function ADL 0.95
Sport/recreation 0.89
QoL 0.90
Total score 0.96Testeretest reliability of the KOOS subdomains and total score was de-
termined with an interval of 2 days18, assuming the probability of a signif-
icant change in symptoms would be absent and the intermediate time too
long for the patient to remember the exact previous answers. The teste
retest reliability was measured with the intra-class-correlation (ICC) co-
efﬁcient with 95% conﬁdence interval, along with the smallest
detectable difference (SDD). An ICC equal or superior to 0.70 is con-
sidered acceptable for testeretest reliability while an ICC of more than
0.80 represents excellent reliability6,8. The SDD indicates the smallest change
that can be distinguished from the measurement error [mean change 1.96
standard deviation (SD) change]6. In addition, the internal consistency was
assessed and Bland and Altman plots were obtained. The internal consis-
tency was measured by the Cronbach’s alpha. A Cronbach’s alpha coefﬁcient
equal or superior to 0.7 is generally considered to be acceptable20. For the
Bland and Altman plots the differences between the ﬁrst and second assess-
ments were plotted against the mean of the two assessments, describing the
distribution of patients along the scoring scale within the 95% limits of
agreement21.
Construct validity was measured by comparing the subdomains of the
KOOS with a priori hypothesized corresponding domains of the comple-
mentary questionnaires (SF-36, Lysholm, EQ-5D). For all a priori hypothe-
ses the Spearman’s rank correlation coefﬁcients were obtained.
Correlations of <0.35, 0.35e0.5 and >0.5 were considered as weak, mod-
erate and strong, respectively. A priori moderateestrong hypothesis of
domains measuring similar constructs was generated according to theoret-
ical hypothesis and the related literature2,9,17: (1) KOOS symptoms with
SF-36 physical functioning; (2) KOOS pain with SF-36 bodily pain and
EQ-VAS; (3) KOOS ADL with the complete SF-36 questionnaire; (4)
KOOS sport and recreation with the Lysholm knee scoring scale; (5)
KOOS QoL with EQ-5D.
The feasibility was assessed by the ﬂoor and ceiling effects. Floor and
ceiling effects were considered to be present if 15% of patients scored the
highest or lowest possible scores6.
The responsiveness was evaluated in another cohort of 36 patients of a re-
cently published randomized trial comparing characterized chondrocyte im-
plantation to microfracturing14. The included patients completed the KOOS
and the Marx activity rating scale (ARS)22 at baseline and 36 months fol-
low-up. The standardized response mean (SRM) and effect size (ES) were
calculated as a measure of responsiveness. ES <0.50, <0.80 and >0.80
were, respectively, considered small, moderate and large.The clinimetric properties were analyzed with SPSS statistical software
version 15.0 (SPSS Inc. Chicago, IL). A P-value of P< 0.05 was considered
to represent a statistically signiﬁcant difference.ResultsPATIENTSOut of the initial 60 contacted patients a total of 46 (re-
sponse 77%) were willing to participate. An additional six
patients were excluded because of missing individual ques-
tionnaire items (n¼ 4) and an insufﬁcient response (n¼ 2)
conforms the testeretest response characteristics. From
the resulting 40 patients (mean age 35 12 years, range
18e55; 70% men), 20 had been treated with autologous
chondrocyte implantation while the other 20 had received
microfracturing. The average postoperative time was 32
months and 87% of the patients had been treated between
January 2005 and July 2006.RELIABILITYTesteretest reliability for the KOOS as determined by the
ICC was 0.97 for the total score whereas the ICCs for the
subdomains ranged from 0.87 to 0.95 (Table I). The SDD
for the subdomains ranged from 4 to 12 points (Table I).
The KOOS internal consistency, as determined by the
Crohnbach’s alpha, was good for the individual subdomains
with Cronbach’s alpha ranging from 0.74 to 0.96 (Table II).
The Bland and Altman representations showed a small indi-
vidual variance between the two assessments for each sub-
domain of the KOOS (Fig. 1).VALIDITYConstruct validity was moderate to high with Spearman’s
rank correlations between the subdomains of the KOOS
and representative subdomains of the SF-36, Lysholm
and EQ-5D ranging from 0.43 to 0.70 (Fig. 2). Moderate
Fig. 1. Bland and Altman plots for the KOOS subdomains show a small individual variance between the two assessments.
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Table III
Floor and ceiling effects of the Dutch KOOS subdomains and total
score
KOOS subdomains Floor effects Ceiling effects
Symptoms 0% 2.6%
Pain 0% 5.1%
Function ADL 0% 7.7%
Sport/recreation 0% 7.7%
QoL 0% 10.3%
Total score 0% 2.6%
Fig. 2. Spearman’s rank correlations for the KOOS subdomains
show moderate to high statistically signiﬁcant correlations between
the subdomains of the KOOS and representative subdomains of
the SF-36, Lysholm and EQ-5D.
1437Osteoarthritis and Cartilage Vol. 17, No. 11correlations were found for the QoL subdomain compared
to EQ-5D and VAS scores (rS¼ 0.43 and 0.44, respec-
tively). The moderate correlations were statistically signiﬁ-
cant at the P¼ 0.006 level (Fig. 2). Strong correlations
were observed for the a priori hypotheses; KOOS symp-
toms and SF-36 physical functioning (rS¼ 0.585), KOOS
pain and SF-36 pain (rS¼ 0.661), KOOS ADL and SF-36
physical functioning (rS¼ 0.558) and KOOS sports and re-
creation and Lysholm (rS¼ 0.700). All strong correlations
were statistically signiﬁcant with P< 0.001(Fig. 2). No a pri-
ori unexpected weak correlations (rS< 0.5) were found.
Floor and ceiling effects were absent (Table III).
The KOOS evaluation showed similar outcomes for both
autologous chondrocyte implantation and microfracturing
patients (Table IV).RESPONSIVENESSThe responsiveness (Table V) was moderate to large,
with the ES ranging from 0.70 to 1.32 and the SRM ranging
from 0.61 to 0.89, and showed a similar range as the ARS
score (ES 0.76, SRM 1.10). The KOOS subdomain function
ADL showed the weakest responsiveness (moderate ES
0.70) while the function in sports and recreation and QoL
subdomains showed large responsiveness (ES 0.98 and
1.32, respectively).Discussion
This study evaluated the clinimetric properties of the
KOOS for a cartilage repair population to validate the
KOOS as an instrument to measure the clinical outcome af-
ter the treatment of a focal, symptomatic cartilage defect in
the knee. This study clearly demonstrates the validity and
reliability of the (Dutch) KOOS after the treatment of focal
cartilage lesions, as shown by the good internal consistency,
moderate to high construct validity and excellent teste
retest reliability. Given the fact that language validated
KOOS versions provide similar outcome for several patientTable IV
KOOS microfracturing vs KOOS ACI. The P-value was calculated
by an independent samples’ t test
KOOS subdomains Mean KOOS (SD) P-value
Microfracturing ACI
Symptoms 74 (21) 74 (12) 0.96
Pain 78 (16) 76 (15) 0.69
Function ADL 85 (16) 83 (13) 0.76
Sport/recreation 60 (27) 51 (25) 0.31
QoL 49 (23) 49 (23) 0.98
Total score 75 (17) 73 (13) 0.66
Table V
KOOS responsiveness vs ARS responsiveness. ES represents the
mean change in score from baseline to 36 months follow-up divided
by the SD of the preoperative score. SRM indicates the mean
change in score from baseline to 36 months follow-up divided by
the SD of the mean change. An effect of <0.50, <0.80 and
0.80 was considered small, moderate and large, respectively
Responsiveness ES SRM
KOOS symptoms 0.72 0.61
KOOS pain 0.82 0.71
KOOS function ADL 0.70 0.75
KOOS sport/recreation 0.98 0.87
KOOS QoL 1.32 0.76
KOOS total score 0.91 0.85
ARS 0.76 1.10
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KOOS are suitable instruments to measure clinical outcome
after the treatment of focal cartilage lesions.
The results for theSpearman’s rank correlations supported
the hypothesized good construct validity. Each subdomain of
the KOOS showed strong correlations with corresponding
domains, except for the KOOS subdomain QoL, which only
showed a moderate correlation to the EQ-5D. This is most
likely due to a difference between themeasured knee-related
QoL (KOOS) and general health-related QoL (EQ-5D). This
idea is supported by the overall higher scores obtained by
the EQ-5D. Although the Lysholm knee scoring scale was
originally designed to assess ligament injuries of the knee,
it proved to demonstrate acceptable clinimetric performance
for outcomes assessment of various chondral disorders of
the knee17. This was supported by the strong correlation be-
tween theKOOSsubdomain function in sports and recreation
and the Lysholm scale obtained in our study. However, sub-
optimal performance of some subdomains of the Lysholm
scale for outcome assessment of various chondral disorders
of the knee has been described as well23.
The KOOS has consistently shown acceptable respon-
siveness for different populations2,6,9. In our study, we dem-
onstrated relatively good responsiveness indicating the
KOOS to be capable of measuring clinical improvement in
patients who have been treated for a focal cartilage lesion
of the knee. The moderate ES score of the KOOS subdo-
mains is most likely a characteristic of the treatment for fo-
cal cartilage lesions instead of moderate responsiveness as
the ARS score showed a similar result.
Since there has been a steady increase in clinical re-
search activity on the repair of focal cartilage lesions in
the previous years, the ﬁeld needs a reliable and detailed
understanding of the clinical outcome. This will play an im-
portant role in assessing the effectiveness of the therapy,
and facilitate its further development. The KOOS consis-
tently proved to be a valid instrument in different languages,
including Dutch, for the quantiﬁcation of OA or the success
of speciﬁc orthopaedic interventions. Recently, the KOOS
was compared to the International Knee Documentation
Committee (IKDC) form to determine which instrument bet-
ter reﬂected the symptoms and disabilities of the cartilage
repair patient24. However, they did not specify the studied
cohort of articular cartilage repair patients and lacked a val-
idation of the questionnaires used. To our knowledge this is
the ﬁrst study to validate the KOOS in a focal articular car-
tilage repair cohort. This can provide a worldwide instru-
ment for the quantiﬁcation of the clinical outcome for this
patient population and increase possibilities for the compar-
ison between (future) clinical trials.Comparison of the KOOS in our study group to age
matched population-based reference data25 shows a lower
score for the cartilage repair group. This indicates that the
instrument is capable to discriminate between healthy sub-
jects and patients after cartilage therapy.
Based on the clinimetric properties presented in the pres-
ent study we conclude that the KOOS questionnaire is
a valid instrument to measure the clinical condition of pa-
tients undergoing treatment of a focal cartilage lesion.
This study provides a basis for the use of the KOOS ques-
tionnaire in future clinical trials on cartilage repair and as
a valid patient-reported, site-speciﬁc instrument in daily clin-
ical practice. A further evaluation of the clinimetric proper-
ties in subgroups, such as age and gender, would be of
great value to provide self-administered questionnaires for
patient speciﬁc subpopulations.Conﬂict of interest
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